Cardiovascular risk and dyslipidemia among persons living with HIV: a review

[1]  A. d’Arminio Monforte,et al.  Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. , 2018, The new microbiologica.

[2]  J. Lake,et al.  Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study , 2017, Antiviral therapy.

[3]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[4]  D. Podzamczer,et al.  Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV , 2017, Expert review of anti-infective therapy.

[5]  P. Vitiello,et al.  Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides. , 2016, International journal of antimicrobial agents.

[6]  R. Gilkeson,et al.  Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection , 2016, AIDS.

[7]  W. Spreen,et al.  Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects , 2016, Clinical pharmacology in drug development.

[8]  M. Farnier.  Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk , 2016, Current Cardiology Reports.

[9]  K. Erlandson,et al.  Fat Matters: Understanding the Role of Adipose Tissue in Health in HIV Infection , 2016, Current HIV/AIDS Reports.

[10]  L. Calza,et al.  Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics. , 2015, Current HIV research.

[11]  G. Rosano,et al.  Safety and efficacy of ezetimibe: A meta-analysis. , 2015, International journal of cardiology.

[12]  J. Kastelein,et al.  PCSK9 inhibition: the way forward in the treatment of dyslipidemia , 2015, BMC Medicine.

[13]  J. Eron,et al.  Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. , 2015, The Lancet. Infectious diseases.

[14]  Jennifer G. Robinson,et al.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[15]  Maciej Banach,et al.  Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies , 2015, BMC Medicine.

[16]  J. Wagner,et al.  A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals , 2015, AIDS.

[17]  Yuan Yuan,et al.  Is the atherosclerotic process accentuated under conditions of HIV infection, antiretroviral therapy, and protease inhibitor exposure? Meta-analysis of the markers of arterial structure and function. , 2015, Atherosclerosis.

[18]  M. Krempf,et al.  ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia , 2015, European heart journal.

[19]  G. McComsey,et al.  Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Malte Kelm,et al.  Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. , 2015, Annals of internal medicine.

[21]  B. Hirschel,et al.  Switch to etravirine for HIV‐positive patients receiving statin treatment: a prospective study , 2015, European journal of clinical investigation.

[22]  Biao Xu,et al.  Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials , 2015, BMC Medicine.

[23]  G. Bondy,et al.  Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients , 2015, Lipids in Health and Disease.

[24]  D. Lloyd‐Jones,et al.  A Systematic Review of the Usefulness of Statin Therapy in HIV-Infected Patients. , 2015, The American journal of cardiology.

[25]  L. V. Van Bortel,et al.  Safety, Tolerability and Pharmacokinetics of Doravirine, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, after Single and Multiple doses in Healthy Subjects , 2015, Antiviral therapy.

[26]  B. Nordestgaard,et al.  Myocardial infarction among Danish HIV-infected individuals: population-attributable fractions associated with smoking. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[28]  M. Lederman,et al.  Rosuvastatin Reduces Vascular Inflammation and T-cell and Monocyte Activation in HIV-Infected Subjects on Antiretroviral Therapy , 2015, Journal of acquired immune deficiency syndromes.

[29]  Kayla R. Stover,et al.  Epidemiology and Management of Antiretroviral-Associated Cardiovascular Disease , 2015, The open AIDS journal.

[30]  I. Grant,et al.  Abdominal Obesity Contributes to Neurocognitive Impairment in HIV-Infected Patients With Increased Inflammation and Immune Activation , 2015, Journal of acquired immune deficiency syndromes.

[31]  D. Swerdlow,et al.  Middle East Respiratory Syndrome Coronavirus: Update for Clinicians , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  R. Ebrahimi,et al.  A Randomized Comparative Trial of Continued Abacavir/Lamivudine plus Efavirenz or Replacement with Efavirenz/Emtricitabine/Tenofovir DF in Hypercholesterolemic HIV-1 Infected Individuals , 2015, PloS one.

[33]  Michael T. Lu,et al.  Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. , 2015, The lancet. HIV.

[34]  W. Shin,et al.  Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis. , 2015, Vascular pharmacology.

[35]  C. Zala,et al.  Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks , 2015, Clinical Drug Investigation.

[36]  F. Raal,et al.  Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[37]  J. Sterne,et al.  Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America , 2015, AIDS.

[38]  M. Glesby,et al.  HIV/AIDS and lipodystrophy: Implications for clinical management in resource-limited settings , 2015, Journal of the International AIDS Society.

[39]  S. Piscitelli,et al.  Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults , 2014, Journal of acquired immune deficiency syndromes.

[40]  S. Piscitelli,et al.  GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects , 2014, Journal of acquired immune deficiency syndromes.

[41]  J. Tomassini,et al.  Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. , 2014, Atherosclerosis.

[42]  J. Meigs,et al.  Links Between Ectopic Fat and Vascular Disease in Humans , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[43]  A. Tang,et al.  Short communication: effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIV-infected persons with hypertriglyceridemia. , 2014, AIDS research and human retroviruses.

[44]  K. White,et al.  Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inf , 2014, The Lancet. Infectious diseases.

[45]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Journal of the American College of Cardiology.

[46]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[47]  G. Watts,et al.  Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. , 2014, Journal of the American College of Cardiology.

[48]  T. Lüscher,et al.  The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. , 2014, European heart journal.

[49]  P. Raggi,et al.  Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis. , 2014, Atherosclerosis.

[50]  J. Gatell,et al.  Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients , 2014, Journal of the International AIDS Society.

[51]  R. Paredes,et al.  Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor–Containing Regimen. Etraswitch Study , 2014, PloS one.

[52]  B. Gazzard,et al.  Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants , 2014, AIDS.

[53]  J. Kahn,et al.  Comparative Effectiveness of Fish Oil Versus Fenofibrate, Gemfibrozil, and Atorvastatin on Lowering Triglyceride Levels Among HIV-Infected Patients in Routine Clinical Care , 2013, Journal of acquired immune deficiency syndromes.

[54]  P. Muret,et al.  Nevirapine–Raltegravir Combination, An Nrti and Pi/R Sparing Regimen, as Maintenance Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients , 2013, Antiviral therapy.

[55]  D. Leaf,et al.  Omega‐3 fatty acid therapy reduces triglycerides and interleukin‐6 in hypertriglyeridemic HIV patients , 2013, HIV medicine.

[56]  G. Guaraldi,et al.  HIV-Associated Lipodystrophy: Impact of Antiretroviral Therapy , 2013, Drugs.

[57]  S. Piscitelli,et al.  Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor , 2013, HIV clinical trials.

[58]  U. Bredeek,et al.  Erratum: SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen (Clinical Infectious Diseases (2013) 56:11 , 2013 .

[59]  Y. Yazdanpanah,et al.  Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients: Final 5-Year Results From STARTMRK , 2013, Journal of acquired immune deficiency syndromes.

[60]  Dolores Corella,et al.  Primary prevention of cardiovascular disease with a Mediterranean diet. , 2013, The New England journal of medicine.

[61]  B. Nordestgaard,et al.  Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  U. Bredeek,et al.  SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  Charles K. Cooper,et al.  No Association of Abacavir Use With Myocardial Infarction: Findings of an FDA Meta-Analysis , 2012, Journal of acquired immune deficiency syndromes.

[64]  D. Podzamczer,et al.  Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir , 2012, AIDS.

[65]  G. McComsey,et al.  Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens. , 2012, AIDS research and human retroviruses.

[66]  D. Podzamczer,et al.  LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. , 2012, Atherosclerosis.

[67]  O. Oguntibeju.  Quality of life of people living with HIV and AIDS and antiretroviral therapy , 2012, HIV/AIDS.

[68]  B. Grinsztejn,et al.  Pooled week 96 results of the phase III DUET‐1 and DUET‐2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest , 2012, HIV medicine.

[69]  W. Weintraub,et al.  Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. , 2012, Atherosclerosis.

[70]  T. Dayspring,et al.  Ezetimibe therapy: mechanism of action and clinical update , 2012, Vascular health and risk management.

[71]  K. White,et al.  Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks , 2012, The Lancet.

[72]  S. Grinspoon,et al.  Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[73]  O. Gabriella,et al.  Ectopic Fat is Linked to Prior Cardiovascular Events in Men With HIV , 2012 .

[74]  Linda M. Spooner,et al.  Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy , 2012, The Annals of pharmacotherapy.

[75]  C. Delaugerre,et al.  Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. , 2011, The Journal of antimicrobial chemotherapy.

[76]  S. Heymsfield,et al.  Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection , 2011, AIDS.

[77]  A. Lazzarin,et al.  Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial , 2011, The Lancet.

[78]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[79]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[80]  J. Falutz.  HIV infection, body composition changes and related metabolic complications: contributing factors and evolving management strategies , 2011, Current opinion in clinical nutrition and metabolic care.

[81]  R. Kronmal,et al.  Reduced Kidney Function and Preclinical Atherosclerosis in HIV-Infected Individuals: The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM) , 2011, American Journal of Nephrology.

[82]  M. Moroni,et al.  Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. , 2011, The new microbiologica.

[83]  Michael S Saag,et al.  Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[84]  E. Ming,et al.  Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. , 2010, The American journal of cardiology.

[85]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[86]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[87]  Rosanna Abbate,et al.  Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. , 2010, The American journal of clinical nutrition.

[88]  D. Potvin,et al.  Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. , 2010, The Journal of clinical endocrinology and metabolism.

[89]  M. Saag,et al.  Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study , 2010, HIV clinical trials.

[90]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[91]  D. Cooper,et al.  Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials , 2010, The Lancet.

[92]  S. Koletar,et al.  Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients , 2009, AIDS.

[93]  D. Fine,et al.  Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment , 2009, AIDS.

[94]  J Shepherd,et al.  The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.

[95]  K. Kotseva,et al.  EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[96]  A. Munnich,et al.  Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease , 2009, Human mutation.

[97]  J. Kastelein,et al.  Combination statin–fibrate therapy: safety aspects , 2009, Diabetes, obesity & metabolism.

[98]  Edward J. Mills,et al.  Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. , 2008, Journal of the American College of Cardiology.

[99]  L. Calza,et al.  Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. , 2008, Current HIV research.

[100]  D. Waters,et al.  Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[101]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[102]  J. Molina,et al.  Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study , 2008, The Lancet.

[103]  S. Heymsfield,et al.  The Associations of Regional Adipose Tissue With Lipid and Lipoprotein Levels in HIV-Infected Men , 2008, Journal of acquired immune deficiency syndromes.

[104]  O. Kirk,et al.  Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.

[105]  C. Fichtenbaum,et al.  Fish Oil and Fenofibrate for the Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy: Results of ACTG A5186 , 2008, Journal of acquired immune deficiency syndromes.

[106]  T. Perneger,et al.  Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006 , 2008, HIV medicine.

[107]  S. Cole,et al.  Longitudinal Anthropometric Patterns Among HIV-Infected and HIV-Uninfected Women , 2008, Journal of acquired immune deficiency syndromes.

[108]  L. Serra-Majem,et al.  Effectiveness of the Mediterranean diet in the elderly , 2008, Clinical interventions in aging.

[109]  D. Potvin,et al.  Metabolic effects of a growth hormone-releasing factor in patients with HIV. , 2007, The New England journal of medicine.

[110]  Hang Lee,et al.  Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. , 2007, The Journal of clinical endocrinology and metabolism.

[111]  C. Ballantyne,et al.  Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. , 2007, Clinical therapeutics.

[112]  Jack Wang,et al.  Long-Term Body Composition and Metabolic Changes in Antiretroviral Naive Persons Randomized to Protease Inhibitor-, Nonnucleoside Reverse Transcriptase Inhibitor-, or Protease Inhibitor Plus Nonnucleoside Reverse Transcriptase Inhibitor-Based Strategy , 2007, Journal of acquired immune deficiency syndromes.

[113]  H. Bays,et al.  Safety considerations with niacin therapy. , 2007, The American journal of cardiology.

[114]  Metabolic,et al.  Fat Distribution in Women With HIV Infection , 2006, Journal of acquired immune deficiency syndromes.

[115]  J. Mckenney,et al.  Statin safety: an assessment using an administrative claims database. , 2006, The American journal of cardiology.

[116]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[117]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[118]  W. K. Henry,et al.  A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. , 2005, AIDS research and human retroviruses.

[119]  D. Podzamczer,et al.  Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine , 2005, AIDS.

[120]  D. Annane,et al.  Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis , 2004, BMJ : British Medical Journal.

[121]  Joel E Gallant,et al.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.

[122]  C. Ballantyne,et al.  Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. , 2004, The American journal of cardiology.

[123]  Archana S. Rao,et al.  Fenofibrate Is Effective in Treating Hypertriglyceridemia Associated with HIV Lipodystrophy , 2004, The American journal of the medical sciences.

[124]  D. Podzamczer,et al.  Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. , 2003, The New England journal of medicine.

[125]  David A. Cooper,et al.  Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy , 2003, AIDS.

[126]  Dannae Brown,et al.  A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia , 2002, AIDS.

[127]  M. Schambelan,et al.  Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. , 2002, The Journal of clinical endocrinology and metabolism.

[128]  P. Durrington,et al.  An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia , 2001, Heart.

[129]  C. Grunfeld,et al.  Fat distribution and metabolic changes in patients with HIV infection. , 1999, AIDS.

[130]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[131]  P. Whelton,et al.  Passive smoking and the risk of coronary heart disease--a meta-analysis of epidemiologic studies. , 1999, The New England journal of medicine.

[132]  G. Chrousos,et al.  The HIV-1 Virion-associated Protein Vpr Is a Coactivator of the Human Glucocorticoid Receptor , 1999, Psychoneuroendocrinology.

[133]  J. Vestbo,et al.  Smoking and risk of myocardial infarction in women and men: longitudinal population study , 1998, BMJ.

[134]  K. Miller,et al.  Visceral abdominal-fat accumulation associated with use of indinavir , 1998, The Lancet.

[135]  Morris Schambelan,et al.  “Buffalo hump” in men with HIV-1 infection , 1998, The Lancet.

[136]  V. Large,et al.  Noradrenaline-induced lipolysis in isolated mesenteric, omental and subcutaneous adipocytes from obese subjects , 1997, International Journal of Obesity.

[137]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[138]  A. d’Arminio Monforte,et al.  Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. , 2016, The new microbiologica.

[139]  G. Ligabue,et al.  Ectopic Fat is Linked to Prior Cardiovascular Events in Men With HIV , 2012, Journal of acquired immune deficiency syndromes.

[140]  M. Moroni,et al.  Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. , 2011, The new microbiologica.

[141]  Ian Graham,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.

[142]  Office on Smoking.  How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General , 2010 .

[143]  A. Catapano.  Perspectives on low-density lipoprotein cholesterol goal achievement. , 2009, Current medical research and opinion.

[144]  S. Trottier,et al.  HIV-associated lipodystrophy syndrome: A review of clinical aspects. , 2005, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[145]  J. Jefferies,et al.  Safety aspects of IT , 1997 .